

BEST OF ESMO

13 - 14 DECEMBER, 2025 | THE ST. REGIS MUMBAI

An ESMO Licensed Event



Hosted by



FOCUSED SESSION ON

RADIATION ONCOLOGY

Pallazio Room | Hall - 2

DAY 1



14 December (Sunday)



09:30 – 16:00

Radiation Oncology | Pallazio Room | Hall - 2

Parallel Session | Breast Malignancies

Chairperson: Dr. Ramesh Bilimagga

09:30 - 09:50	5 MINS	389P	A Competing Risk Analysis Model to Explore the Impact of Postoperative Radiotherapy for Sentinel Lymph Node Micrometastases or ITCs in Female Breast Cancer Speaker: Dr. Durva Kurkure
	5 MINS	388P	Long-Term Outcomes of Intraoperative Radiotherapy (IORT) in Early Breast Cancer (eBC) Speaker: Dr. Shreya Kunder
	5 MINS	576P	Simultaneous integrated boost (sib) intensity-modulated radiotherapy for treatment of bone metastases: late analysis of a breast cancer cohort Speaker: Dr. Shwetha Mutha
	5 MINS	342P	Decoding Male Breast Cancer: A Molecular Perspective on Diagnosis and Treatment Speaker: Dr. Revathy

Moderators: Dr. Tabassum W

09:50 - 10:10	PANEL DISCUSSION 20 MINS	<i>Panel Discussion on Impact on India Practice based on above abstracts</i>	Panelists Dr. Manish Chandra Dr. Deepak Dangwal Dr. Sanjay MH, Pune Dr. Amrita S Dr. Namrata Bhagat
10:10 - 10:20	INVITED TALK 10 MINS	Topic: Expert Comments Speaker: Dr. Sumit Basu	

Parallel Session | Head & Neck Malignancies

Chairperson: Dr. Shyam K Shrivastava

10:20 - 10:50	5 MINS	1320O	Postoperative adjuvant radiochemotherapy with cisplatin (aRCH) vs. aRCH plus pembrolizumab in locally advanced head and neck squamous cell carcinoma (HNSCC): First data of the ADRISK trial Speaker: Dr. Koustav Majumdar
	5 MINS	1321O	Concurrent Chemoradiotherapy with/without Adjuvant Capecitabine in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Controlled Phase III Trial Speaker: Dr. Shwetabh Sinha
	5 MINS	1322O	A phase III randomized trial of prophylactic radiation with 2-step40 versus SIB56 IMRT techniques for locally advanced squamous cell carcinoma of the head and neck (JCOG1912, NEW BRIDGE) Speaker: Dr. Anuj Kumar
	5 MINS	1328MO	Hypofractionated radiotherapy of single tumor lesion increases systemic response rate to pembrolizumab in recurrent or metastatic head and neck cancer (R/M-HNSCC): Primary endpoint of the randomized Keynote-717 trial Speaker: Dr. Pooja N Patel
	5 MINS	1332P	A phase II study of SBRT followed by neoadjuvant chemo immunotherapy of Sintilimab plus docetaxel and cisplatin for in locoregionally advanced squamous cell carcinoma of oral cavity and oropharynx Speaker: Dr. Samir Batham
	5 MINS	1467E	Neoadjuvant SBRT sequential Tislelizumab in locally advanced head and neck squamous cell carcinoma: A single-arm, phase II trial (NEOSTART study). Speaker: Dr. Ritika Hinduja

Moderators: Dr. Gagan Saini

10:50 - 11:10	PANEL DISCUSSION 20 MINS	<i>Panel Discussion on Impact on India Practice based on above abstracts</i>	Panelists Dr. Riddhi J Talukdar Dr. Rohit Malde Dr. Samarpita Dr. Renjeet Bajpai Dr. HIRAK Vyas, Ahmedabad Dr. Sharbani G Laskar Dr. Ashwini Budrukar
11:10 - 11:20	INVITED TALK 10 MINS	Topic: Expert Comments Speaker: Dr. Sarbani G Laskar	
11:20 - 11:30	INVITED TALK 10 MINS	Topic: Expert Comments Speaker: Dr. Ashwini Budrukar	

Parallel Session | Lung Malignancies

Chairperson: Dr. Nagraj Huligol

11:30 - 12:05	4 MINS	1786O	External validation of AI for early-stage lung cancer recurrence prognosis using CT radiomics Speaker: Dr. Guncha Maheshwari
	4 MINS	2760MO	Intracranial activity of ifinatamab deruxtecan (I-DXd) in patients (pts) with extensive-stage (ES) small cell lung cancer (SCLC) and baseline (BL) brain metastases (BM): Primary analysis of IDEATE-Lung01 Speaker: Dr. Kinjal Jani
	4 MINS	1847MO	Activity of Ziplertinib Against Active Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring EGFR Exon 20 Insertion (Ex20ins)/Other Uncommon Mutations Speaker: Dr. Mahesh Upasani
	4 MINS	1818MO	Surgery versus radiotherapy after induction therapy with serplulimab combined with chemotherapy for unresectable stage IIIB-IIIC non-small cell lung cancer: a randomized controlled, open-label, phase 2 trial Speaker: Dr. Bhavin Visariya
	4 MINS	LBA72	NorthStar: A Phase II Randomized Study of Osimertinib (OSI) With or Without Local Consolidative Therapy (LCT) for Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Speaker: Dr. Deep S Pruthi
	4 MINS	1797P	Clinical risk stratification for lung nodules: evidence from a non risk based lung cancer screening in a Chinese cohort Speaker: Dr. Roshan Patil
	4 MINS	1794P	Global quantitative assessment of multidisciplinary team (MDT) care in early-stage NSCLC Speaker: Dr. Unmesh M
	4 MINS	1795P	SMARCA4, c-MET and PD-L1 expression in pN2 non-small cell lung cancer from LungART IFCT 0503 trial. Speaker: Dr. Prashant Nayek
	4 MINS	1807EP	Prospective Cohort Study Comparing Characteristics and Outcomes of Octogenarians with Early-Stage (T1a-b; ≤20 mm) NSCLC Treated by Stereotactic Body Radiation Therapy or Surgery Speaker: Dr. Ramesh Purohit

Moderators: Dr. Kaustav Talapatra

12:05 - 12:25	PANEL DISCUSSION 20 MINS	<i>Panel Discussion on Impact on India Practice based on above abstracts</i>	Panelists <i>Dr. Nikhil Kalyani</i> <i>Dr. Pranav C</i> <i>Dr. Madan Maitre</i> <i>Dr. Mangesh Patil</i> <i>Dr. Prasad Tanawade</i> <i>Dr. Manas Senapati</i>
12:25 - 12:35	INVITED TALK 10 MINS	<i>Topic: Expert Comments</i> <i>Speaker: Dr. JP Agarwal</i>	
12:35 - 12:45	INVITED TALK 10 MINS	<i>Topic: Expert Comments</i> <i>Speaker: Dr. Kaustav Talapatra</i>	
12:45 - 13:15	30 MINS	LUNCH BREAK	

Parallel Session | Genito Urinary Malignancies

Chairperson: Dr. Sharmila Agarwal

13:15 - 14:00	5 MINS	LBA89	A randomized phase 2 study of ¹⁷⁷ Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21 Speaker: Dr. Priyamvada
	5 MINS	2595MO	Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment Speaker: Dr. Jay Sahu
	5 MINS	2390P	Associations between quantitative baseline ⁶⁸ Ga-PSMA-11 PET parameters and ¹⁷⁷ Lu-PSMA-617 efficacy in the PSMAfore study Speaker: Dr. Nasim Shaikh
	5 MINS	2400P	Utilising the CHAARTED and STAMPEDE2 criteria in the Prostate Specific Membrane Antigen Positron Emission Tomography (PSMA PET) era: Implications on outcomes in metastatic prostate cancer (mPC) Speaker: Dr. Saurabha Kumar
	5 MINS	2386P	A phase I/II trial of combined Radium-223 and Lutetium-177 PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC): First analysis of the AlphaBet trial Speaker: Dr. Pranav C
	5 MINS	2391P	LuPARP: Phase 1 trial of [¹⁷⁷ Lu]Lu-PSMA-617 (LuPSMA) and olaparib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). Speaker: Dr. Sandeep De
	5 MINS	2389P	Final analysis of patients treated with [¹⁷⁷ Lu]Lu-PSMA-617 in early access program in metastatic castration-resistant prostate cancer (mCRPC) in France. Speaker: Dr. Bhoosan Zade
	5 MINS	2392P	PCPro as a prognostic plasma lipidomic biomarker in TheraP (ANZUP 1603): a randomised trial of [¹⁷⁷ Lu]Lu-PSMA-617 (LuPSMA) vs cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) Speaker: Dr. Jatin Bhatia
	5 MINS	2387P	¹⁷⁷ Lu-PSMA-617 in Oligometastatic Hormone Sensitive Prostate Cancer (BULLSEYE) Speaker: Dr. Parth Verma

Moderators: Dr. Trinanjan Basu

14:00 - 14:20	PANEL DISCUSSION 20 MINS	<i>Panel Discussion on Impact on India Practice based on above abstracts</i>	Panelists Dr. Priyamvada Dr. Bhoosan Zade, Pune Dr. Kinjal Jani Dr. Kaustav Talapatra Dr. Saurabha Kumar Dr. Gagan Saini, Delhi. Dr. Vaibhav Sonwani,
14:20 - 14:30	INVITED TALK 10 MINS	Topic: Expert Comments Speaker: Dr. V Kannan	

Parallel Session | Gynecological & GI Malignancies

Chairperson: Dr Manish Chandra

14:30 - 15:15	15 MINS	2231P	Modified FOLFIRINOX with or without stereotactic body radiation (SBRT) in patients with locally advanced pancreatic cancer (LAPC): Randomized phase 2 SABER trial Speaker: Dr. Shiv K Gudi
	15 MINS	1088P	Metastasis-directed stereotactic radiotherapy (mdSBRT) for patients (pts) with oligoprogressive, oligorecurrent or oligopersistent (oligo-pr/re/pe) high grade ovarian cancer (HGOC) Speaker: Dr. Prachi Sawant
	15 MINS	887EP	Optimal Timing of SBRT Combined with Immune Checkpoint Inhibitors in MSS Colorectal Liver Metastases: A Real-World Cohort Study with Immune Microenvironment Analysis Speaker: Dr. Shanu Jain

Moderators: Dr. Rahul K

15:15 - 15:35	PANEL DISCUSSION 20 MINS	<i>Panel Discussion on Impact on India Practice based on above abstracts</i>	<i>Panelists Dr. Shreyasi Karmakar Dr. Sagar Gayakwad Dr. Vaibhav Sonwani Dr. Mayuresh Virkar Dr. Akshay Mangaj Dr. Maitri Gandhi</i>
15:35 - 16:00	INVITED TALK 25 MINS	<i>Session Summary & Takeways Speaker: Dr. Shyam Srivastava, Dr. Ramesh Bilimagga</i>	